QRON 0.40 Qrons Inc.
| Range: | 0.1557-0.36945 | Vol Avg: | 0 | Last Div: | 0 | Changes: | 0.03 |
| Beta: | 0.76 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Tue Sep 12 2017 | Empoloyees: | 2 | ||
| CUSIP: | 74737F101 | CIK: | 0001689084 | ISIN: | US74737F1012 | Country: | US |
| CEO: | Mr. Jonah Martin Meer | Website: | https://qrons.com | ||||
Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. Qrons Inc. was incorporated in 2016 and is based in Long Island City, New York.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow